Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 6B, 2008, Pages 2628-2643

  Mohr, Andrea ^a   Lyons, Mark ^a   Deedigan, Laura ^a   Harte, Tina ^a   Shaw, Georgina ^a   Howard, Linda ^a   Barry, Frank ^a   O'Brien, Tim ^a   Zwacka, Ralf ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Adenovirus; Apoptosis; Lung cancer; Mesenchymal stem cells; TRAIL

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; DRUG SCREENING; ERYTHROCYTE; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; LEUKOCYTE; LUNG TUMOR; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; T LYMPHOCYTE; TRANSGENE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ERYTHROCYTES; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKOCYTES; LUNG NEOPLASMS; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 56249091888     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00317.x     Document Type: Article

References (42)

1. McMahon JM, Conroy S, Lyons M, Greiser U, O'shea C, Strappe P, Howard L, Murphy M, Barry F, O'Brien T. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev. 2006 15 : 87 96.
2. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mito-genic stimuli. Blood. 2002 99 : 3838 43.
3. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 2003 10 : 228 41.
4. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 75 : 389 97.
5. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 105 : 1815 22.
6. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, Aboody K, Padovan C, Straube A, Tonn JC, Goldbrunner R. Vascular endothelial growth factor A contributes to gliomainduced migration of human marrow stromal cells (hMSC). Exp Neurol. 2006 199 : 301 10.
7. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006 24 : 1254 64.
8. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005 65 : 3307 18.
9. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol. 2007 86 : 8 16.
10. Lusky M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther. 2005 16 : 281 91.
11. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003 80 : 148 58.
12. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002 9 : 979 86.
13. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 1997 4 : 1069 76.
14. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997 8 : 37 44.
15. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999 6 : 1574 83.
16. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministra-tion. Hum Gene Ther. 1999 10 : 2515 26.
17. Yang Y, Xiang Z, Ertl HC, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA. 1995 92 : 7257 61.
18. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD. Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. Mol Ther. 2006 14 : 118 28.
19. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther. 2006 6 : 215 26.
20. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001 8 : 341 8.
21. Myhre S, Henning P, Granio O, Tylo AS, Nygren PA, Olofsson S, Boulanger P, Lindholm L, Hong SS. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther. 2006 14 : 376 81.
22. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006 441 : 239 43.
23. Chen XC, Wang R, Zhao X, Wei YQ, Hu M, Wang YS, Zhang XW, Zhang R, Zhang L, Yao B, Wang L, Jia YQ, Zeng TT, Yang JL, Tian L, Kan B, Lin XJ, Lei S, Deng HX, Wen YJ, Mao YQ, Li J. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis. 2006 27 : 2434 41.
24. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther. 2006 5 : 755 66.
25. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 1997 416 : 329 34.
26. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 277 : 818 21.
27. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, Osborne R, Cheu M, Lieberman G, Lum BL. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol Annual Meeting Proceedings Part I. 2006 24 : 3047.
28. Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N, Howard T, Ullrich S, Tolcher A, Sikic B. HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J Clin Oncol Annual Meeting Proceedings Part I. 2006 24 : 3012.
29. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000 165 : 2886 94.
30. Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin KM, Weiher H, Fisher KJ, Zwacka RM. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther. 2004 11 : 534 43.
31. Wenger T, Mattern J, Haas TL, Sprick MR, Walczak H, Debatin KM, Buchler MW, Herr I. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. 2007 14 : 316 26.
32. Germano IM, Uzzaman M, Benveniste RJ, Zaurova M, Keller G. Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2006 105 : 88 95.
33. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004 36 : 568 84.
34. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991 139 : 271 9.
35. Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW, Han SK, Shim YS, Lee CT. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 2003 10 : 540 8.
36. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing lig-and (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 9 : 164 72.
37. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther. 2002 9 : 1262 70.
38. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol. 2003 22 : 1241 5.
39. Ratajczyak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczyak MZ. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006 20 : 847 56.
40. Aliotta JM, Sanchez-Guijo FM, Dooner GJ, Johnson KW, Dooner MS, Greer KA, Greer D, Pimentel J, Kolankiewicz LM, Puente N, Faradyan S, Ferland P, Bearer EL, Passero MA, Adedi M, Colvin GA, Quesenberry PJ. Alteration of Marrow Cell Gene Expression, Protein Production and Engraftment into Lung by Lung-derived Microvesicles: A Novel Mechanism for Phenotype Modulation. Stem Cells. 2007 25 : 2245 56.
41. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by an horizontal transfer of mRNA. Blood. 2007 110 : 2440 8.
42. Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007 18 : 627 41.